These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23884058)

  • 41. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.
    Evon DM; Verma A; Dougherty KA; Batey B; Russo M; Zacks S; Shrestha R; Fried MW
    Dig Dis Sci; 2007 Nov; 52(11):3251-8. PubMed ID: 17394072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness.
    Rifai MA; Moles JK; Short DD
    Psychiatr Serv; 2006 Apr; 57(4):570-2. PubMed ID: 16603757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychiatric management of the hepatitis C patient.
    Rifai MA; Indest D; Loftis J; Hauser P
    Curr Treat Options Gastroenterol; 2006; 9(6):508-19. PubMed ID: 17081484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches.
    Willenbring ML
    AIDS; 2005 Oct; 19 Suppl 3():S227-37. PubMed ID: 16251823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?
    Spennati A; Pariante CM
    Psychol Med; 2013 Jun; 43(6):1127-32. PubMed ID: 22975198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mental Disorders and Interferon Nontreatment in Hepatitis C Virus Infection-a Population Based Cohort Study.
    Chiu WC; Lu ML; Chang CC
    Psychiatry Investig; 2020 Mar; 17(3):268-274. PubMed ID: 32151125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toward Optimal Control of Hepatitis C Virus Infection in Persons With Substance Use Disorders.
    Talal AH; Thomas DL; Reynolds JL; Khalsa JH
    Ann Intern Med; 2017 Jun; 166(12):897-898. PubMed ID: 28437796
    [No Abstract]   [Full Text] [Related]  

  • 48. HIV/hepatitis C virus co-infection: basic, behavioral and clinical research in mental health and drug abuse.
    Joseph J; Stoff DM; van der Horst C
    AIDS; 2005 Oct; 19 Suppl 3():S3-7. PubMed ID: 16251825
    [No Abstract]   [Full Text] [Related]  

  • 49. Expanding the Scope of Integrated Behavioral Health Care for Patients With Hepatitis C Virus.
    Pyne JM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):2015-6. PubMed ID: 25952310
    [No Abstract]   [Full Text] [Related]  

  • 50. Management of common psychiatric conditions in the HIV-positive population.
    Brogan K; Lux J
    Curr HIV/AIDS Rep; 2009 May; 6(2):108-15. PubMed ID: 19358782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C virus infection and substance abuse. Proceedings of a conference, 11-13 November 2003, Washington, DC, USA.
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S259-378. PubMed ID: 17024735
    [No Abstract]   [Full Text] [Related]  

  • 52. [Skin Diseases in Primary Psychiatric Disorders].
    Mavrogiorgou P; Juckel G
    Fortschr Neurol Psychiatr; 2016 Oct; 84(10):608-616. PubMed ID: 27788552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.
    Trask PC; Esper P; Riba M; Redman B
    J Clin Oncol; 2000 Jun; 18(11):2316-26. PubMed ID: 10829053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C: mental health issues.
    Rowe W; Rowe J; Malowaniec L
    Can J Public Health; 2000; 91 Suppl 1():S42-4, S45-8. PubMed ID: 11059133
    [No Abstract]   [Full Text] [Related]  

  • 55. Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases.
    Serota DP; Barocas JA; Springer SA
    Clin Infect Dis; 2020 Feb; 70(5):968-972. PubMed ID: 31420651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychiatric Adverse Effects Of Interferon Therapy.
    Coman HG; Herţa DC; Nemeş B
    Clujul Med; 2013; 86(4):318-20. PubMed ID: 26527969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Addiction to ephedrine in psychiatric disorders.
    Martínez-Quintana E; Rodríguez-González F
    Adicciones; 2013; 25(1):89-90. PubMed ID: 23487283
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of hepatitis C and drug addiction: is the development of "clinically significant" fibrosis a good decision-making criterion?].
    Lucidarme D; Filoche B
    Gastroenterol Clin Biol; 2004; 28(6-7 Pt 1):529-31. PubMed ID: 15243384
    [No Abstract]   [Full Text] [Related]  

  • 59. [Psychopathological comorbidity of obesity].
    Ayensa JI; Calderon MJ
    An Sist Sanit Navar; 2011; 34(2):253-61. PubMed ID: 21904407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Letter to the Editor in response to the recently published article "Roncero C, Buch B, Martin-Sanchez AM, et al. Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis. Gastroenterol Hepatol. 2022".
    Cuadrado A; Cabezas J; Crespo J
    Gastroenterol Hepatol; 2023 Mar; 46(3):214. PubMed ID: 35964813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.